Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.
Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.